Avita Medical To Present At 2015 Stem Cell Meeting On The Mesa

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - October 05, 2015) - Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced that Vice President of Research and Technology Andrew Quick will present at the upcoming 2015 Stem Cell Meeting on the Mesa being held October 7-9 in La Jolla, CA.

In his presentation, Mr. Quick will discuss recent and upcoming clinical, regulatory, and commercial milestones for its portfolio of skin regeneration solutions, including the ongoing US FDA Pivotal Trial of lead product, ReCell®, which is used in the treatment of a wide range of burns.

Most recently, Avita announced that it had been awarded a US government contract with the Biomedical Advanced Research and Development Authority (BARDA) worth up to $53.9 million for late-stage clinical development and procurement of its ReCell® Autologous Cell Harvesting Device under a US mass casualty preparedness program. To date, more than 6,000 patients have been safely treated with ReCell®, which is approved for use in Europe, Canada, Australia, China and Taiwan, and is protected by a portfolio of patents worldwide, the most recent of which was validated in 11 European countries.

Following are logistical details of Mr. Quick's presentation during the Company Presentations portion of the Partnering Forum:
Date: Wednesday, October 7
Time: 5:45 p.m. PT
Location: La Jolla Ballroom 2, at the Estancia La Jolla Hotel

"Stem Cell Meeting on the Mesa is one of the most-regarded conferences exclusively focused on regenerative medicine," said Andrew Quick, VP Research and Technology at Avita Medical. "We look forward to providing business and clinical updates, including, most notably, our new contract with BARDA to provide inventory of ReCell® under a U.S. mass casualty preparedness program and which will also support our ongoing U.S. FDA Pivotal trial of ReCell® in burns."

The Presentation will be live webcasted on http://stemcellmeetingonthemesa.com/webcast/ and published on Avita Medical's YouTube channel shortly after the event.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the Stem Cell Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the regenerative medicine and advanced therapies industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first and only event of its kind dedicated solely to facilitating connections in this sector. Combined, these meetings attract nearly 800 attendees, fostering key partnerships through more than 500 one-on-one meetings while highlighting the significant clinical and commercial progress in the field over the past year.

ABOUT RECELL® AND RES™
ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

ABOUT AVITA MEDICAL LIMITED
Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal US trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit www.avitamedical.com.